+272.5%
SNDK vs MRNA
+909.7%
-637.2%
-65.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -22.3% | -6.5% | -15.7% | -22.1% |
| 7D | -39.4% | +8.4% | -47.8% | -39.5% |
| 30D | -51.4% | +28.8% | -80.2% | -51.7% |
| 3M | -40.3% | +329.2% | -369.5% | -45.5% |
| 6M | -42.7% | +416.9% | -459.6% | -55.0% |
| YTD | +239.7% | +718.8% | -479.1% | +74.2% |
| 1Y | +272.5% | +924.9% | -652.4% | +43.8% |
| All | +272.5% | +909.7% | -637.2% | +43.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling